Latest Breaking News On - Seanr smith - Page 1 : comparemela.com

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, ...

- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

ImmunOs Therapeutics Announces Appointment of Joseph

- Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD,.

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

ImmunOs Therapeutics Raises $74M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!